initi coverag
let time initi buy
biopharma upsid capit deploy reason buy
sustain high singl digit biopharma revenu growth driven mix
share gain strength inclus patheon organ calcul
healthi end market along continu strength china outgrow
peer support organ growth forecast ahead
consensu forecast upsid combin materi ep upsid plu
ebit expans take publish ep year compound-annual-growth-rate forecast
warrant anoth turn price-to-earnings expans
ub evid lab survey scenario model support view
survey reveal acceler budget growth life scienc equip
consum improv spend mass spec chromatographi person
ub evid lab pharma servic survey reveal high singl digit growth biolog
develop posit patheon analysi biopharma mix support
superior growth rate vs peer
 offer upsid
analysi balanc sheet capac rang deal multipl financ
synergi assumpt indic gener ep upsid via
cumul year given success compani recent larg deal
pthn feic expect potenti addit posit catalyst
valuat discount dcf primari method
discount cash flow primari valuat method cross check trade
multipl yield pt incorpor wacc lt growth
rate pt impli ntm price-to-earnings price-to-earnings current price-to-earnings
premium year averag ntm price-to-earnings rel
trade data key metric
compani account thomson reuter ub estim metric mark ub analyst adjust appli valuat base averag share price year base
share price oct edt
report prepar ub secur llc analyst certif requir disclosur begin
page ub seek busi compani cover research report result investor
awar firm may conflict interest could affect object report investor consid
report singl factor make invest decis
 strong contribut biopharma china key thermo
deliv organ growth biopharma china sustain
see four reason thermo biopharma growth remain higher
 thermo track record success though target
multipl elev fewer opportun within core tool market
past level success repeat
see ep upsid next year
 above-averag margin expans key contributor
compani consist double-digit ep growth much room left
guidanc margin expans look reason
initi coverag thermo fisher scientif inc octob
ub research thesi map guid think report
 strong contribut biopharma china key thermo deliv
organ growth biopharma china sustain growth rate
ye biopharma thermo largest custom revenu expect growth
sustain driven custom mix share gain patheon comp
continu strong growth china thermo total china busi grow low mid-
teen tariff relat impact risk see limit impact biopharma drive total
organ consensu
 thermo track record success though target multipl elev
fewer opportun within core tool market past level success repeat
believ compani proven track record creat valu acquisit
recent two feic patheon amongst compani best ever still see ampl
opportun within compani exist market calcul acquisit add upsid
ep growth next year
 above-averag margin expans key contributor compani consist
double-digit ep growth much room left margin expans
long term guidanc ebit expans look achiev us
assum base busi margin improv per year line histor averag
despit thermo greater scale leverag today
expect growth consensu larg part due bullish stanc thermo
biopharma outlook faster top line continu ebit expans drive ep growth
expand mid-teen ep growth benefit
ub evid lab survey cro/clin trial manufactur cmc support posit
view biopharma fundament competit posit biopharma budget
consensu forecast organ growth estim use revers dcf stock
discount organ growth ebit expans averag
upsid downsid
thermo fisher scientif inc nyse global diversifi manufactur distributor life
scienc tool diagnost sell scientif instruments/equip
initi coverag thermo fisher scientif inc octob
biopharma exposur nearli revenu
evid lab survey biopharma manag
support acceler budget
capit deploy opportun add
ep
trade long-term premium
far certain peer
sourc exhibit compani data ub research ub evid lab
initi coverag thermo fisher scientif inc octob
 strong contribut biopharma china
key thermo deliv organ
growth biopharma china sustain
ye biopharma thermo largest custom revenu
expect growth sustain driven custom
mix share gain patheon comp continu strong growth china
thermo total china busi grow low mid-teen tariff
relat impact risk see limit impact biopharma drive total
organ growth consensu
biopharma ub evid lab survey plu analysi patheon deal
support call continu strength thermo biopharma
custom group bullish view thermo china deriv
dilig numer expert research govern polici
ub china biopharma research call acceler domest
spend china tariff scenario analysi help quantifi downsid risk
valuat expand price-to-earnings
price-to-earnings premium two strong year stock perform
market still give credit superior organ revenu ep
growth view consensu expect low organ growth
forecast dcf primari valuat methodolog
support pt assum turn price-to-earnings expans
though expect ep rise henc impli pt multipl lower
see four reason thermo biopharma
growth remain higher longer
first thermo mix within biopharma segment like under-appreci
lead exposur faster grow sub-seg bioproduct clinic trial
logist high end molecular consum key driver
second thermo scale product leadership breadth drive share gain
third fold faster-grow patheon acquisit add nearli
growth alon
fourth despit tariff develop china remain key driver
develop biopharma acceler growth biopharma region
initi coverag thermo fisher scientif inc octob
thermo biopharma growth robust past year grow nearli
faster tool industri growth rate
period thermo revenu exposur biopharma sector
climb via organ growth plu particular patheon acquisit
current total revenu larger exposur
compani biggest custom base academic/govern
initi coverag thermo fisher scientif inc octob
henc outlook custom group critic assess
compani growth outlook biopharma contribut
compani organ growth last year
initi coverag thermo fisher scientif inc octob
figur thermo organ growth biopharma drive total growth
figur thermo organ growth biopharma contribut growth
thermo tool group histor heavili expos spend
typic grow rang set better understand
driver thermo industri rapid growth biopharma
custom segment provid thermo grow biopharma high singl digit
rate high convict compani grow within state
rang bia toward mid/upp end higher
initi coverag thermo fisher scientif inc octob
figur need growth non-biopharma grow total
rest thermo
achiev growth need
guidanc
often discuss life scienc tool compani custom growth
trend presum custom group homogen across differ
quit opposit extent revenu exposur vari
significantli within custom group tool compani
differ busi mix henc grow differ level driven
thermo biopharma growth rate enabl compani mix
busi custom group one orient toward faster
grow biolog drug product clinic trial servic plu share gain
view evolut current biopharma revenu mix via strateg
 organ invest key abil sustain market
lead growth choos right market make right invest
focus right deal combin technic servic expertis
posit outgrow larg cap tool peer year come
initi coverag thermo fisher scientif inc octob
thermo mix toward faster grow area key reason growth
superior peer
initi coverag thermo fisher scientif inc octob
figur thermo biopharma revenu faster grow area
growth contribut
work ub evid lab survey biopharma custom across
us europ assess numer factor associ spend
consum servic vendor prefer
level growth spend prioriti
budget higher end basic equipment/consum acceler
mass spec chromatographi budget improv posit
bare use today/th futur posit
survey biopharma lab manag predomin us
eu represent univers cover pre-
commerci biopharma commerci stage
biopharma budget instrument consum acceler
bode well
initi coverag thermo fisher scientif inc octob
figur posit outlook biopharma budget growth life scienc
equip consum expect acceler
addit budget basic consum equip also
improv particularli import given lab product
figur budget basic lower end consum also improv
product specif budget mass spec budget improv along
step back grow high-singl biopharma
expect continu easi tie back low-singl digit
growth mass spec chromatographi budget level growth
alway case sinc conduct biopharma lab survey take
big delta come reason mix captur
servic big driver peer price new
product expect yy peer constant innov may
initi coverag thermo fisher scientif inc octob
pick suffic say improv budget posit although
make analog model
share mass spec usag amongst biopharma
respond yy expect chang statist signific
initi coverag thermo fisher scientif inc octob
follow acquisit dionex becam bigger player
chromatographi water agil still domin tradit liquid
chromatographi given high attach rate mass spec
chromatographi stand reason grow share
chromatographi market industri check support
survey hold share
initi coverag thermo fisher scientif inc octob
survey feedback posit front almost usag
today lab product expect chang futur
figur distribut share share stableamzn
direct vendor
sigma aldrich part merck kgaa vwr
pthn bioproduct
revenu bioproduct market repres thermo
biopharma exposur across equip patheon contract drug
manufactur busi growth segment histor
well excess low singl digit biopharma trend bioproduct
histor mid-teen patheon grown mid-to-high singl digit
initi coverag thermo fisher scientif inc octob
though expect low doubl digit given benefit leverag
exclud patheon thermo exposur bioproduct market repres
biopharma revenu contribut nearli
segment growth compani lead provid cell cultur use
upstream portion biolog drug product also provid
singl use solut chromatographi product media
instrument solut busi grown low mid doubl digit
past year macro outlook remain robust growth
continu number drug pipelin grown last
year wherea biolog drug grown rate
outlook continu robust
figur biolog drug pipelin grown last year
number compound
pharmaproject informa pharma intellig author note slowdown impact
author thorough scrub databas henc realist prior year growth bit
less thu rate chang higher seen
patheon deal open address market thermo
signific opportun organ inorgan share gain given patheon
market share across serv segment
patheon transact close august manag time
deal announc character address market grow mid-
singl high-singl digit patheon similarli grow rate year-end
commentari indic busi grew mid-singl digit
similarli guidanc incorpor mid-singl digit growth
result patheon revenu outlook rais mid-singl digit
high-singl digit bump result closer
year
initi coverag thermo fisher scientif inc octob
expect patheon maintain growth rate bia higher
thermo sever year come due sever factor
first overal market grow mid-to-high singl digit patheon
signific share gain opportun given fragment natur
second importantli agre manag bullish
assert sale pipelin opportun close deal greatli
enhanc patheon part thermo abl leverag c-
suit custom relationship scale breadth
guidanc revenu synergi year impli
organ growth patheon think base organ
assumpt plu synergi target low
ub evid lab survey inquir biopharma custom
regard budget outsourc trend within portion chemistri
manufactur control biolog drug product
initi coverag thermo fisher scientif inc octob
figur biolog outsourc lot room leftrat increas next
yr though slowli
year today
maxim budget outsourc
actual budget outsourc
initi coverag thermo fisher scientif inc octob
figur vendor reput relationship import price
becom less import
pthn biolog busi larg compris activ across
drug substanc drug product front budget
acceler last year combin
continu outsourc penetr support end market growth
consist base market outlook pthn layer top expect
share gain get growth potenti pthn
manag commentari sinc deal close quit posit
grow bullish time
ahead thought go base
chanc meet quit number custom first
four month year encourag feedback
go underli part patheon businessif
look demand demand profil strong sell-side confer
month sinc announc transact go
excit thing visit custom
execut part busi amaz
custom access abil us acceler growth
feel good go great abl
rais outlook busi last two quarter
recent manag indic patheon fei potenti
best deal ever done patheon potenti
transform thermo-fish transact
initi coverag thermo fisher scientif inc octob
given time patheon close revenu includ
part organ growth wherea remain part
organ growth result inclus patheon add
biopharma growth year next year ad nearli
compani total organ growth
figur pthn growth contribut total
pthn total revenu
pthn organ revenu
pthn impact organ growth
biopharma segment
thermo
china signific driver peer remain today
interestingli within china thermo largest busi industri appli
custom segment wherea custom group lower
rel revenu weight china compar global weight
remain bullish continu strong growth china clearli
concern china growth exposur countri risen
trade/tariff tension continu escal pleas see life scienc tool
diagnost sector report date octob report includ section
china impact tool
lay exposur compani well
recent growth trend contribut total growth china enabl
assess posit secular driver place continu strong growth
discuss current tariff impact includ detail explan
impact
evalu variou scenario compani depend upon
outcom tariff polici base ub global macro team
analysi impact global growth assum differ tariff
outcom assess outcom could impact
tool compani revenu ep stock price perspect
initi coverag thermo fisher scientif inc octob
 thermo track record success
though target multipl elev
fewer opportun within core tool
market past level success
believ compani proven track record creat valu
acquisit recent two feic patheon amongst
compani best ever still see ampl opportun within
compani exist market estim acquisit add upsid
ep growth next year
analysi past deal understand manag approach
evalu opportun within core market model impact
thermo discount valuat price-to-earnings dcf basi vs peer current
impli littl upsid price share
see ep upsid next year
near top mani investor question concern decis invest
thermo fisher sever question relat
compani buy next
impact futur deal upon thermo busi financi
result strateg impact compar past deal futur deal
modest financi impact histor one given thermo much
compani conduct acquisit market outsid current core
big deal would compani consid
investor day manag discuss address market
opportun compani captur share patheon
acquisit give thermo entri fragment contract develop
manufactur market repres increas compani
initi coverag thermo fisher scientif inc octob
figur revenu vs
figur market share pthn open space
rest industri
achiev similar financi impact past deal compani would need
larger larger deal inher entail greater
execut risk
activ seri smaller deal make harder
achiev level financi strateg impact prior deal
said argument could made last year yet
compani recent sizabl acquisit patheon fei
strong start wide discuss potenti compani two best
manag deliv strong track record success
acquisit multipl risen time compani benefit
favor financ environ shrewd time strong execut aid
initi coverag thermo fisher scientif inc octob
compani ppi busi system on-going rise interest rate present
headwind manag part also serv
depress deal multipl
compani strong track record past deal ad lead
technolog platform capabl gener signific synergi
strateg via enter adjac market allow ampl cross-sel
addit materi financi impact open new market opportun
prove long runway ppi busi improv result favor
given larg proport intang get incorpor invest
capit base follow compani well mani peer
aggress acquir said compani
remain focus expand despit dilut impact
deal gener target achiev particular deal excess
compani wacc year five post deal given benefit compani
 strategi low level reason avoid invest
thermo view
given strong free cash flow gener continu ampl opportun
proven track record continu see attract opportun ahead add
initi coverag thermo fisher scientif inc octob
manag target capit deploy
 remain buyback
dividend averag target leverag assum calcul
compani deploy toward time assum max leverag
say ev/ebitda acquisit multipl estim compani
could gener ep accret futur asid
anticip strateg benefit would like unfold given compani
initi coverag thermo fisher scientif inc octob
min bs
use
size deal
size deal
acquir revenu take ev/revenu multipl
ep accret impact lost buy-back
ep accret account reduc buyback
model bake futur rather model buybacks/year
believ conserv fcf/year forecast
initi coverag thermo fisher scientif inc octob
figur leverag start
addit even hi leverag scenario figur year
deliv estim compani would
manag laid investor day present ep target
rang ep compound-annual-growth-rate assum middl
outcom hi leverag scenario analysi combin
aggress buy-back given
still ampl balanc sheet cash arriv ep year
initi coverag thermo fisher scientif inc octob
 above-averag margin expans
key contributor compani consist
double-digit ep growth much room left
margin expans
long term guidanc ebit expans look
achiev us assum base busi margin improv
per year line histor averag despit thermo greater scale
analysi compani histor margin expans continu
lever manag dispos enabl futur margin expans plu
dilig thermo histor success drive margin expans acquir
believ market assum margin expans line compani
guidanc margin expans
compani ebit margin expand past year
period expans
almost exclus driven gross margin expand
nearli expans occur
driven acquisit life
technolog gross margin expect show modest
declin wherea oper margin expand
initi coverag thermo fisher scientif inc octob
figur histor gm ebit margin expans
figur gm ebit margin trend
initi coverag thermo fisher scientif inc octob
figur breakdown margin driver
figur sg trend
compani margin impact factor period
make difficult assess underli oper margin trend name fx
life transact close februari drove gross margin
expans alon though impact oper margin less
own life higher opex load
recent pthn acquisit close august neg
impact oper margin expect anoth
oper contract contract own pthn much lower
gross margin compar gross margin
currenc notabl drag margin oper
margin modestli
initi coverag thermo fisher scientif inc octob
net fx compani underli oper margin expand
averag past year line compani project
base ex expans target
figur impact margin fx oper
given track record oper margin improv proven sigma-
like oper disciplin practic process improv ppi along
compani increas scale product leadership plu histori deliv
 synergi view compani margin expans target
reason conserv
initi coverag thermo fisher scientif inc octob
analyz employe satisfact score across host differ metric
insight exercis work ub evid lab perform analysi
glassdoor trend across number stock
review glassdoor review pertain
overal satisfact across broad spectrum life scienc tool diagnost
pharma servic medic technolog stock overal satisfact
 peer group
figur overal employe satisfact modestli
averag peer group
overal satisfact rate star
johnson johnson
ceo approv ceo marc casper receiv approv rate slightli
peer group averag
initi coverag thermo fisher scientif inc octob
figur ceo approv averag
initi coverag thermo fisher scientif inc octob
primari valuat method discount cash flow support price
review methodolog input
along life scienc tool peer trade price-to-earnings multipl near
high end histor absolut rang part driven favor end market
fundament strong global economi
improv organ growth outlook combin strong execut
competit posit balanc sheet option warrant higher
absolut rel valuat multipl
initi coverag thermo fisher scientif inc octob
figur ntm price-to-earnings rel
figur ntm ev/ebitda rel
discount cash flow primari valuat metric support
price valuat base upon wacc lt growth
assumpt util year explicit forecast period includ detail
financi model thru intermedi forecast beyond
saniti check dcf analysi assess forward price-to-earnings price target multipl
impli price impli ntm price-to-earnings multipl rel
price-to-earnings compar current ntm price-to-earnings multipl
initi coverag thermo fisher scientif inc octob
million us except per share amount
invest work capit
equiti
assum cost debt
debt end current year
end current year
net debt cash end current year
dilut sharecount end current year
capital-expenditure revenu
chang wc chang revenu
current month fiscal year
market valu equiti
rel impli current
initi coverag thermo fisher scientif inc octob
upsid downsid
upsid organ growth driven strong
biopharma growth oper margin expans ep upsid via
accret gener ep compound-annual-growth-rate price-to-earnings multipl
base case
base dcf-deriv assum wacc lt growth
assumpt util year explicit forecast period includ detail
financi model intermedi forecast beyond
price impli price-to-earnings multipl rel price-to-earnings appli ep
forecast compar current ntm price-to-earnings multipl
downsid organ growth compound-annual-growth-rate oper margin contract
lead ep compound-annual-growth-rate price-to-earnings contract
base price-to-earnings
initi coverag thermo fisher scientif inc octob
relat consum
thermo fisher scientif inc nyse global
diversifi manufactur distributor life scienc tool
diagnost sell scientif instruments/equip
along
environment lab oper four segment
specialti diagnost lab product servic
thermo fisher base waltham massachusett
revenu aggreg somewhat faster global
expand margin faster rate averag
 compani current sweet spot
mani compani grow histor averag lead
elev valuat multipl result tri
identifi compani uniqu posit product
cycl elev growth expect well
look opportun valuat disloc
due temporari factor diagnost pure-play
secular dynam
less favor tool
compani given price pressur regulatori issu less
scalabl busi model although innov first
mover advantag creat attract opportun
revenu end market segment mix
initi coverag thermo fisher scientif inc octob
ub evid lab provid research analyst rigor primari research team
conduct repres survey key sector decision-mak mine internet systemat
collect observ data pull inform innov sourc appli
varieti advanc analyt techniqu deriv insight data collect valuabl
resourc suppli ub analyst differenti inform support forecast
recommendationsin turn enhanc abil serv need client
ub evid lab conduct on-line survey lab execut work within
respond mix compani without commerci
product major base us remain base europ
primarili uk germani spain
pharmaceut
ub evid lab conduct on-line survey pharma biotech execut
control discoveri preclin clinic clinic trial suppli budget major
respond manager/director level remain vice-president svp c-
suit level respond align mix therapeut area strong
diabetes/metabol diseas half respond compani headquart
us hq europ japan remain region
oncolog cv
ub evid lab analyz current employe review glassdoor lead career websit
measur trend employe satisfact metric ceo approv across compani
life scienc diagnost sector analysi focus employe moral follow
sever ceo chang across industri includ approxim current employe
review data review current septemb
ub evid lab data scienc team systemat analyz data set earn call
transcript quantifi sentiment topic discuss call analysi base
proprietari algorithm develop team sentiment analysi use pre-defin lexicon
word identifi extent text contain posit neg sentiment
properli account context topic analysi indic extent discuss around
set word base observ frequenc data set
initi coverag thermo fisher scientif inc octob
profit tax
profit tax
equival
invest asset
trade payabl st liabil
net incom pref div
net chang work capit
chang debt pref share
flow inc/ dec cash
balanc sheet inc/ dec cash
compani account ub estim ub metric use report figur adjust ub ep ub dilut calcul use ub net incom ad back depreci
initi coverag thermo fisher scientif inc octob
buy minor
revenu divis us
ebit ub divis us
compani account ub estim ub metric use report figur adjust ub analyst
initi coverag thermo fisher scientif inc octob
valuat method risk statement
discount cash flow primari valuat method dcf incorpor
wacc lt growth assumpt
industry-wid risk includ declin spend pharmaceut compani
due signific declin fund small compani promin
trial failur affect class drug deceler global growth
includ risk escal trade tension pressur academ
govern budget could result recessionari cost-cut
polit chang price pressur diagnost sector due
protect access medicar act pama chang competit dynam
includ disrupt new entrant certain technolog inabl
compani compet effect china critic growth market foreign
exchang fluctuat chang tax polici
risk
includ biopharma slow chines economi
integr recent larg make bad strateg decis futur
initi coverag thermo fisher scientif inc octob
